Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| GlaxoSmithKline | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
HIV-uninfected children born to HIV+ women have low level heart problems at birth which may predispose them to heart failure, arrythmias and heart attack later in life. The impact of these heart problems on future heart health is unclear as it is unknown if heart problems in these children persist, worsen or resolve in pre-pubescence. The objective of this study is to characterize heart function in HIV-negative pre-pubertal children born to HIV+ women and exposed to HIV and HAART in utero and compare them to age and gender matched healthy children born to HIV-negative women. Through this objective we will determine if heart problems in HIV-negative children born to HIV+ women and exposed to HAART in utero persists, worsens, or resolves during pre-pubescence.
Significance:
Approximately 700,000 children annually are born to HIV-infected mothers throughout the world, but with the advent of perinatal highly active antiretroviral therapy (HAART), the majority of children are born uninfected in Westernized nations and those uninfected are increasing in developing nations. Uninfected children exposed to HIV and HAART in utero, have subclinical left ventricular dysfunction (LVD) at birth which may predispose them to heart failure, conduction abnormalities and myocardial infarction later in life. The impact of this LVD on future cardiac risk is unclear as it is unknown if LVD in these children persist, worsen or resolve in pre-pubescence.
Study objectives:
The objective of this study is to characterize left ventricular function in HIV-negative pre-pubertal children born to HIV+ women and exposed to HIV and HAART in utero and compare them to age and gender matched healthy children born to HIV-negative women. Through this objective we will determine if LVD in HIV-negative children born to HIV+ women and exposed to HAART in utero persists, worsens, or resolves during pre-pubescence. If LVD persists or worsens in pre-pubescence, these data will lead to future studies examining mechanisms of and treatments for LVD in these children and will significantly impact the clinical monitoring and care of these children. If LVD resolves during pre-pubescence, then these data will provide important information that clinical cardiac monitoring may not be critical in this population.
Methods:
We plan to examine left ventricular function in 30 HIV-negative children born to HIV+ women and exposed to HAART in utero and compare them to 30 healthy age and gender matched children born to HIV-negative women. Left ventricular function will be examined by 2-D, Doppler and Tissue Doppler imaging echocardiography using a General Electric Vivid 7® ultrasound machine. Left ventricular measures will include left ventricular structure and dimensions, systolic and diastolic flow rates, wall velocities during systole and diastole and systolic and diastolic strain and strain rates (sensitive measures of myocardial contractility). Echocardiographic measures will take place in the Cardiovascular Imaging Laboratory (CVIL) at Washington University School of Medicine by a certified cardiac ultrasonographer and data will be processed, analyzed and interpreted by the ultrasonographer, a consulting cardiologist and the principal investigator.
Outcomes:
Primary outcomes will include measures of left ventricular function: left ventricular mass, left ventricular end diastolic dimension, fractional shortening, systolic and diastolic wall velocities (tissue Doppler imaging) and systolic and diastolic strain and strain rates (2-D speckle tracking methodology).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Healthy Control | HIV-negative children born to healthy, HIV-negative women | ||
| Exposed to HIV/HAART | HIV-negative children exposed to HIV and HAART in utero |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Left Ventricular Mass Index | left ventricular mass index measured by 2D echocardiography | Baseline |
| Fractional Shortening | Fractional shortening measured by M-mode cardiography | Baseline |
| Measure | Description | Time Frame |
|---|---|---|
| Global Strain Rate | Myocardial deformation (a measure of heart contractility) measured by speckel tracking echocardiography | Baseline |
| Systolic Myocardial Velocity During Systole (S') | Systolic myocardial velocity during systole measured by tissue Doppler echocardiography |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
HIV-negative children will be recruited through their HIV+ mothers who are seen at the AIDS Clinical Trials Unit at Washington University and surrounding St. Louis community clinics. HIV-negative children will be recruit through Washington University and surrounding St. Louis pediatric clinics, and through Washington University Volunteers for Health service.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| William T Cade, PhD | Washington University School of Medicine | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Washington University School of Medicine | St Louis | Missouri | 63110 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 22874520 | Result | Cade WT, Waggoner AD, Hubert S, Krauss MJ, Singh GK, Overton ET. Reduced diastolic function and left ventricular mass in HIV-negative preadolescent children exposed to antiretroviral therapy in utero. AIDS. 2012 Oct 23;26(16):2053-8. doi: 10.1097/QAD.0b013e328358d4d7. |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Healthy Control | HIV-negative children born to healthy, HIV-negative women |
| FG001 | Exposed to HIV/HAART | HIV-negative children exposed to HIV and HAART in utero |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Healthy Control | HIV-negative children born to healthy, HIV-negative women |
| BG001 | Exposed to HIV/HAART | HIV-negative children exposed to HIV and HAART in utero |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Left Ventricular Mass Index | left ventricular mass index measured by 2D echocardiography | Posted | Mean | Standard Deviation | g/m2 | Baseline |
|
|
1 year
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Healthy Control | HIV-negative children born to healthy, HIV-negative women No adverse events |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| William T. Cade | Washington University | 314-286-1432 | tcade@wustl.edu |
Not provided
| ID | Term |
|---|---|
| D015658 | HIV Infections |
| ID | Term |
|---|---|
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D015229 | Sexually Transmitted Diseases, Viral |
Not provided
Not provided
Not provided
Not provided
Not provided
| Baseline |
| Early to Late Diastolic Filling Ratio | Early to late diastolic filling ratio measured by tissue Doppler echocardiography | Baseline |
| Myocardial Wall Velocity During Early Diastole | Myocardial wall velocity during early diastolemeasured by tissue Doppler imaging | Baseline |
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
|
|
|
| Primary | Fractional Shortening | Fractional shortening measured by M-mode cardiography | Posted | Mean | Standard Deviation | percentage of full contraction | Baseline |
|
|
|
|
| Secondary | Global Strain Rate | Myocardial deformation (a measure of heart contractility) measured by speckel tracking echocardiography | Posted | Mean | Standard Deviation | percentage of full deformation | Baseline |
|
|
|
|
| Secondary | Systolic Myocardial Velocity During Systole (S') | Systolic myocardial velocity during systole measured by tissue Doppler echocardiography | Posted | Mean | Standard Deviation | cm/s | Baseline |
|
|
|
|
| Secondary | Early to Late Diastolic Filling Ratio | Early to late diastolic filling ratio measured by tissue Doppler echocardiography | Posted | Mean | Standard Deviation | ratio, unitless | Baseline |
|
|
|
|
| Secondary | Myocardial Wall Velocity During Early Diastole | Myocardial wall velocity during early diastolemeasured by tissue Doppler imaging | Posted | Mean | Standard Error | cm/s | Baseline |
|
|
|
|
| 0 |
| 30 |
| 0 |
| 30 |
| EG001 | Exposed to HIV/HAART | HIV-negative children exposed to HIV and HAART in utero No adverse events | 0 | 30 | 0 | 30 |
Not provided
Not provided
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |